Protective Effect Of Aspartate Ornithine On Hepatic Ischemic Reperfusion Injury In Patients With Primary Liver Cancer

BackgroundPrimary liver cancer is a malignant tumor with a high mortality rate in China.It is characterized by a stealthy,rapid progression,aggressive nature and high degree of malignancy.Although there are many ways to treat hepatocellular carcinoma,surgical treatment of hepatocellular carcinoma is still the most effective method.Because the liver has multiple blood supply,intraoperative bleeding is easy,the method of blocking hepatic portal blood supply is usually used to reduce bleeding.Hepatic blood flow occlusion and refluxing can cause a series of metabolic disorders,leading to hepatic ischemia-reperfusion injury(HIRI),and even systemic inflammatory response or serious consequences such as liver failure which could affect the prognosis.Postoperative drug intervention has a protective effect on liver ischemia-reperfusion injury.Ornithine aspartate injection could slow down the progress of ischemia-reperfusion injury and alleviate vascular endothelial cell injury.The purpose of this study was to study the application of ornithine aspartate injection in patients undergoing hepatectomy for hepatocellular carcinoma(HCC),and to understand the safety and protective effect of this drug on HIRI,and to provide evidences for the clinical treatment.ObjectiveTo investigate the changes of blood routine,liver and kidney function,cytokines and life signs in patients with hepatocellular carcinoma(HCC)undergoing hepatectomy by Pringer's method and the effect of ornithine aspartate injection on the indexes of HCC patients.To study the safety and protective effect of the drug on HIRI.Methods101 patients with PLC were recruited in our hospital between October 2016 and March 2018,and all patients with PLC received partial resection of hepatectomy.After operation,the patients were divided into control(n=50)and observation(n=51)group,receiving conventional supporting treatment and those in the observation was treated with intravenous ornithine aspartate injection.Serum malondialdehyde(MDA),superoxide dismutase(SOD),nitric oxide(NO)and endothelin-1(ET-1)levels were assayed.ResultsAt the end of 7 day treatment,serum MDA level was significantly lower than in the control [(5.4±0.6)?mol/L vs.(7.3±0.9)?mol/L],serum ET-1 level was also significantly lower than in the control [(115.2±14.3)pg/L vs.(216.6±26.8)pg/L],while serum SOD level in the observation was much higher than in the control [(18.6±2.3)U/mL vs.(13.3±1.6)U/mL],and serum NO level was also significantly higher than in the control [(37.9±5.7)?mol/L vs.(22.5±3.1)?mol/L,P<0.05];serum bilirubin level in the observation group was(23.4±7.7)?mol/L,much lower than in the control(31.3±7.8)?mol/L(P<0.05);there was no significant difference to the routine blood parameters in the two groups(P>0.05).ConclusionInjection of aspartate ornithine can reduce liver ischemia-reperfusion injury and protect liver function in patients with liver cancer resection.